BRTX vs CYTK vs MDGL vs MESO vs FATE

For growth investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger pick with 432. 1% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Analysts rate Cytokinetics, Incorporated (CYTK) a "Buy" — based on 34 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Madrigal Pharmaceuticals, Inc.

(MDGL) delivered a total return of +310. 1%, compared to -99. 4% for BioRestorative Therapies, Inc. (BRTX). Over 10 years, the gap is even starker: MDGL returned +39. 2% versus BRTX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Madrigal Pharmaceuticals, Inc.

(MDGL) is the lower-risk stock at 0. 57β versus BioRestorative Therapies, Inc. 's 2. 21β — meaning BRTX is approximately 290% more volatile than MDGL relative to the S&P 500. On balance sheet safety, Mesoblast Limited (MESO) carries a lower debt/equity ratio of 21% versus 59% for Madrigal Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Madrigal Pharmaceuticals, Inc.

(MDGL) is pulling ahead at 432. 1% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: BioRestorative Therapies, Inc. grew EPS 53. 0% year-over-year, compared to -24. 3% for Cytokinetics, Incorporated. Over a 3-year CAGR, BRTX leads at 105. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Madrigal Pharmaceuticals, Inc.

(MDGL) is the more profitable company, earning -30. 1% net margin versus -22. 4% for BioRestorative Therapies, Inc. — meaning it keeps -30. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDGL leads at -31. 3% versus -28. 8% for BRTX. At the gross margin level — before operating expenses — MDGL leads at 94. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cytokinetics, Incorporated (CYTK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), +817. 2% 10Y return). BioRestorative Therapies, Inc. (BRTX) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CYTK: +817. 2%, BRTX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BRTX is a small-cap high-growth stock; CYTK is a small-cap high-growth stock; MDGL is a mid-cap high-growth stock; MESO is a small-cap high-growth stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.